TNGX
+$0
10,000 sh
TNGX
Tango Therapeutics, Inc.
SEC CIK 1819133
$27.97
+120.4% · 90 days
90-day buys
$0
0 open-market
90-day sells
$2.97M
7 open-market
Net insider flow
−$2.97M
Net selling
Filings shown
68
Most recent
Advertisement
At a glance
Over the last 90 days, insiders at TNGX have sold a net $2.97M of stock (0 open-market buys vs 7 sells).
Largest recent trade: Third Rock Ventures Iv, L.p. sold $7.71M of TNGX, trimming their stake 7%.
Most active filer: Third Rock Ventures Iv, L.p., with 24 transactions among the recent filings shown.
Insider transaction history
Form 4 filings for TNGX, newest firstTNGX
−$4.85M
477,401 sh @ $10
TNGX
−$4.01M
500,000 sh @ $8
TNGX
−$2.56M
363,541 sh @ $7
TNGX
Third Rock Ventures Iv, L.p. sold $608.6K of TNGX, trimming their stake 1%.
−$608.6K
86,459 sh @ $7
Advertisement
TNGX
−$4.5M
642,906 sh @ $7
TNGX
−$2.12M
302,194 sh @ $7
TNGX
−$7.71M
1.1M sh @ $7
TNGX
−$12.5K
3,948 sh @ $3
TNGX
−$21.7K
6,851 sh @ $3
TNGX
−$28.5K
9,013 sh @ $3
TNGX
−$12.8K
4,284 sh @ $3
TNGX
−$22.2K
7,432 sh @ $3
TNGX
−$29.2K
9,778 sh @ $3
TNGX
Rothenberg Mace, TNGX's Director, spent $37.8K of their own money on 10,000 shares at $4, growing their stake 47%.
+$37.8K
10,000 sh @ $4
TNGX
Rothenberg Mace, TNGX's Director, spent $36.2K of their own money on 10,000 shares at $4, growing their stake 89%.
+$36.2K
10,000 sh @ $4
TNGX
−$709.8K
67,400 sh @ $11
TNGX
−$867.1K
75,000 sh @ $12
TNGX
−$2.03M
175,000 sh @ $12
TNGX
−$288.7K
25,000 sh @ $12
TNGX
−$1.51M
150,000 sh @ $10
TNGX
−$1.32M
135,000 sh @ $10
TNGX
−$392K
40,000 sh @ $10
TNGX
Third Rock Ventures Iv, L.p. sold $993.4K of TNGX, trimming their stake 1%.
−$993.4K
100,000 sh @ $10
TNGX
Third Rock Ventures Iv, L.p. sold $931.1K of TNGX, trimming their stake 1%.
−$931.1K
95,000 sh @ $10
TNGX
−$492K
50,000 sh @ $10
TNGX
Third Rock Ventures Iv, L.p. sold $992.8K of TNGX, trimming their stake 1%.
−$992.8K
100,599 sh @ $10
TNGX
−$1.96M
200,000 sh @ $10
TNGX
−$1.22M
125,000 sh @ $10
TNGX
−$2.57M
262,740 sh @ $10
Advertisement
About TNGX insider activity
This page tracks every recent Form 4 filed for Tango Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.
The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.
Frequently asked questions
How often is TNGX insider data updated?
Continuously. We read from SEC EDGAR, so new Form 4 filings for Tango Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.
What does "net insider flow" mean?
It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.
Why do some rows show grants or option exercises instead of buys?
Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.
Is this investment advice?
No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.